CD1D and neuroblastoma: Traditionally, NK T-cell therapy has been used to target tumor cells, and while neuroblastoma tumor cells do not express CD1d, studies have found that inducing exogenous CD1d expression in neuroblastoma tumor cells with pulsed α-Galactosylceramide activated NK T cells and produced NK T cell anti-tumor activity (177).